Free Trial
TSE:CMED

CanniMed Therapeutics (CMED) Stock Price, News & Analysis

CanniMed Therapeutics logo

About CanniMed Therapeutics Stock (TSE:CMED)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
52,208 shs
Average Volume
387,394 shs
Market Capitalization
C$668.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CanniMed Therapeutics Inc. operates as a plant biopharmaceutical company that specializes in medical cannabis. The company cultivates and sells pharmaceutical-grade cannabis products in dried herbal and oil forms for Canadian patients. It also offers herbal cannabis and cannabis oil; and vaporizers, consumable vaporizer accessories, and herb mills. In addition, the company offers a plant biotechnology research and product development program that focuses on the production of plant-based materials for pharmaceutical, agricultural, and environmental applications. CanniMed Therapeutics Inc. was founded in 1988 and is based in Saskatoon, Canada. As of March 28, 2018, CanniMed Therapeutics Inc. operates as a subsidiary of Aurora Cannabis Inc.

Receive CMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CanniMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CMED Stock News Headlines

CanniMed Therapeutics Inc (CMED)
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
See More Headlines

CMED Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that CanniMed Therapeutics investors own include Aurora Cannabis (ACB), Canopy Growth (WEED), Cronos Group (MJN), Aphria (APHA), Leaf Mobile (LEAF), Hydropothecary (THCX) and Cronos Group (CRON).

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
TSE:CMED
CIK
N/A
Fax
N/A
Employees
147,000
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
24,757,000
Free Float
N/A
Market Cap
C$668.44 million
Optionable
Not Optionable
Beta
N/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (TSE:CMED) was last updated on 5/1/2018 by MarketBeat.com Staff.
From Our Partners